AUROPHARMAAurobindo Pharma Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
2 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
2 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹10263 Cr | ₹1124 Cr | 15.83% | 10.95% | ₹19.57 | 17.5x |
| Q1 FY2027 | ₹9150 Cr | ₹1032 Cr | 15.24% | 11.28% | ₹17.86 | 15.9x |
| Q4 FY2026 | ₹8853 Cr | ₹921 Cr | 14.39% | 10.40% | ₹15.86 | 14.2x |
| Q3 FY2026 | ₹8646 Cr | ₹910 Cr | 15.14% | 10.52% | ₹15.67 | 15.4x |
| Q2 FY2026 | ₹8286 Cr | ₹848 Cr | 15.08% | 10.24% | ₹14.61 | 14.4x |
| Q1 FY2026 | ₹7868 Cr | ₹824 Cr | 15.22% | 10.48% | ₹14.20 | 13.3x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.